Professional Documents
Culture Documents
Terzah M Horton, MD, Overview of the treatment of acute lymphoblastic leukemia in children and adolescents, UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com (Accessed on November
11, 2017.)Kumar V, Abbas AK, Aster JC. (2015) "Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus". Robbins and Cotran Pathologic Basis od Disease, 9th edition, Cap 13, Elsevier
CONSOLIDACIN E INTENSIFICACIN (4-8 meses)
Destruir clulas residuales que sobrevivieron a etapa previa.
CONSOLIDACION
Fase relativamente carente de toxicidad para permitir la recuperacin del
tratamiento intensivo previo
-Citarabina
-Metotrexato
-Antraciclinas (daunorrubicina, doxorrubicina)
-Agentes alquilantes (ciclofosfamida, ifosfamida)
-Epipodofilotoxinas (etopsido, etopofosphamida)
INTENSIFICACION (5-8 SEM)
Fase intensiva tarda de tratamiento (intensificacin tarda)
Quimioterapia igual o similar a fase de induccin.
Terzah M Horton, MD, Overview of the treatment of acute lymphoblastic leukemia in children and adolescents, UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com
(Accessed on November 11, 2017.)Kumar V, Abbas AK, Aster JC. (2015) "Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus". Robbins and Cotran Pathologic Basis od
Disease, 9th edition, Cap 13, Elsevier
Destruir los ltimos vestigios de leucemia
residual
Medicamentos que interfieren sntesis de
ADN
MANTENIMIENTO -dosis diaria de mercaptopurina
-una dosis semanal de metotrexato
(2-3 aos) -En consecuencia produciendo
mielosupresion.
Quimioterapias intermitentes de vincristina
y un corticoide.
Terzah M Horton, MD, Overview of the treatment of acute lymphoblastic leukemia in children and adolescents, UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com (Accessed on November 11, 2017.)Kumar V, Abbas AK, Aster JC.
(2015) "Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus". Robbins and Cotran Pathologic Basis od Disease, 9th edition, Cap 13, Elsevier
NCCN Guidelines for Patients (2017) "Acute Lymphoblastic
Leukemia". Guidelines For Patients, Version 1.2017